Signs That Your Trading Will Ruin Your Retirement - March 03, 2020

by Zacks Equity Research Published on March 03,2020

From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.

• MRK Quick QuoteMRKPositive Net Change
• ISBC Quick QuoteISBCPositive Net Change
• NXRT Quick QuoteNXRTNegative Net Change

• 401k-contributions
• 401k-plan
• retirement
• retirement-cost
• retirement-savings
• retirement-timeline

Merck's Keytruda Improves PFS in Phase III Lymphoma Study

by Zacks Equity Research Published on March 03,2020

Merck's (MRK) Keytruda significantly improves progression-free survival compared with brentuximab vedotin in patients with relapsed or refractory classical Hodgkin Lymphoma (cHL)

• PFE Quick QuotePFEPositive Net Change
• MRK Quick QuoteMRKPositive Net Change
• GSK Quick QuoteGSKPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change

• pharmaceuticals

Top Analyst Reports for Merck, Novartis & Mondelez

by Mark Vickery Published on March 03,2020

Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Novartis (NVS) and Mondelez International (MDLZ).

• NVS Quick QuoteNVSPositive Net Change
• NOW Quick QuoteNOWNegative Net Change
• MRK Quick QuoteMRKPositive Net Change
• MDLZ Quick QuoteMDLZPositive Net Change
• GD Quick QuoteGDPositive Net Change
• DE Quick QuoteDEPositive Net Change

• aerospace
• agriculture
• computers
• consumer-staples
• industrial-products
• pharmaceuticals

Dow Logs Worst One-Day Slump in History: ETF & Stock Winners

by Sanghamitra Saha Published on February 28,2020

Dow Jones saw the worst single-day slump on Thursday. While inverse Dow Jones ETFs gained considerably, these stocks too were less hurt.

• MSFT Quick QuoteMSFTNegative Net Change
• XOM Quick QuoteXOMPositive Net Change
• INTC Quick QuoteINTCNegative Net Change
• AAPL Quick QuoteAAPLPositive Net Change
• PFE Quick QuotePFEPositive Net Change
• WMT Quick QuoteWMTPositive Net Change
• MMM Quick QuoteMMMNegative Net Change
• MRK Quick QuoteMRKPositive Net Change
• DOW Quick QuoteDOWPositive Net Change
• WBA Quick QuoteWBAPositive Net Change
• USO Quick QuoteUSOPositive Net Change
• DIA Quick QuoteDIAPositive Net Change
• DOG Quick QuoteDOGNegative Net Change
• SDOW Quick QuoteSDOWNegative Net Change
• DXD Quick QuoteDXDNegative Net Change

Simple Secrets Anyone Can Use to Reach Early Retirement - February 28, 2020

by Zacks Equity Research Published on February 28,2020

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

• JACK Quick QuoteJACKPositive Net Change
• MRK Quick QuoteMRKPositive Net Change
• LMT Quick QuoteLMTPositive Net Change

• 401k-contributions
• 401k-plan
• retirement
• retirement-cost
• retirement-savings
• retirement-timeline
• retiring-early

Esperion (ESPR) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research Published on February 28,2020

Esperion Therapeutics (ESPR) reports encouraging fourth-quarter results. The company is set to launch its first drug next month.

• SNY Quick QuoteSNYPositive Net Change
• MRK Quick QuoteMRKPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change
• ESPR Quick QuoteESPRPositive Net Change

• earnings
• pharmaceuticals

Exelixis (EXEL) Beats on Earnings, Misses on Sales in Q4

by Zacks Equity Research Published on February 26,2020

Exelixis' (EXEL) Q4 results are a mixed bag, as earnings beat, while sales marginally miss estimates.

• RHHBY Quick QuoteRHHBYPositive Net Change
• PFE Quick QuotePFEPositive Net Change
• MRK Quick QuoteMRKPositive Net Change
• EXEL Quick QuoteEXELNegative Net Change

• biotechs
• earnings

This is Why Merck (MRK) is a Great Dividend Stock

by Zacks Equity Research Published on February 24,2020

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

• MRK Quick QuoteMRKPositive Net Change

• dividend
• dividend-stocks
• dividend-yield
• high-growth
• income-investor

The Extreme Risks of Trading Your Own Retirement Assets - February 24, 2020

by Zacks Equity Research Published on February 24,2020

From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.

• MRK Quick QuoteMRKPositive Net Change
• NXRT Quick QuoteNXRTNegative Net Change
• FMNB Quick QuoteFMNBPositive Net Change

• 401k-contributions
• 401k-plan
• retirement
• retirement-cost
• retirement-savings
• retirement-timeline

Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y

by Zacks Equity Research Published on February 21,2020

Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.

• MRK Quick QuoteMRKPositive Net Change
• UTHR Quick QuoteUTHRPositive Net Change
• CORT Quick QuoteCORTPositive Net Change
• KALV Quick QuoteKALVPositive Net Change

• pharmaceuticals

Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval

by Kinjel Shah Published on February 21,2020

AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.

• JNJ Quick QuoteJNJPositive Net Change
• SNY Quick QuoteSNYPositive Net Change
• AZN Quick QuoteAZNNegative Net Change
• RHHBY Quick QuoteRHHBYPositive Net Change
• PFE Quick QuotePFEPositive Net Change
• MRK Quick QuoteMRKPositive Net Change
• NVS Quick QuoteNVSPositive Net Change

• pharmaceuticals

Moderna (MRNA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research Published on February 21,2020

Progress of its pipeline candidates is likely to have increased Moderna's (MRNA) operating expenses in the fourth quarter.

• AZN Quick QuoteAZNNegative Net Change
• MRK Quick QuoteMRKPositive Net Change
• MRNA Quick QuoteMRNAPositive Net Change
• VCEL Quick QuoteVCELPositive Net Change

• biotechs

Roche's Tecentriq sBLA for Lung Cancer Gets Priority Review

by Kinjel Shah Published on February 20,2020

Roche (RHHBY) gets FDA's priority review status for a sBLA for Tecentriq monotherapy in first-line treatment of certain people with advanced non-small cell lung cancer.

• AZN Quick QuoteAZNNegative Net Change
• RHHBY Quick QuoteRHHBYPositive Net Change
• MRK Quick QuoteMRKPositive Net Change
• BMY Quick QuoteBMYPositive Net Change

• pharmaceuticals

Powerful Proof Anyone Can Invest for an Early Retirement - February 20, 2020

by Zacks Equity Research Published on February 20,2020

Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.

• MRK Quick QuoteMRKPositive Net Change
• LMT Quick QuoteLMTPositive Net Change
• HTBK Quick QuoteHTBKPositive Net Change

• 401k-contributions
• 401k-plan
• retirement
• retirement-cost
• retirement-savings
• retirement-timeline
• retiring-early

NewLink (NLNK) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research Published on February 18,2020

Investors are looking forward to updates on NewLink's (NLNK) merger with Lumos Pharma, when the former releases fourth-quarter 2019 results.

• MRK Quick QuoteMRKPositive Net Change
• AMAG Quick QuoteAMAGPositive Net Change
• NLNK Quick QuoteNLNKPositive Net Change
• VCEL Quick QuoteVCELPositive Net Change

• biotechs

AstraZeneca's (AZN) Q4 Earnings and Sales Miss Estimates

by Zacks Equity Research Published on February 14,2020

AstraZeneca (AZN) misses estimates for earnings and sales. However, new drugs, mainly cancer medicines, continue to drive product sales higher.

• AZN Quick QuoteAZNNegative Net Change
• MRK Quick QuoteMRKPositive Net Change
• NVS Quick QuoteNVSPositive Net Change
• VRTX Quick QuoteVRTXPositive Net Change

• earnings
• pharmaceuticals

Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails

by Kinjel Shah Published on February 14,2020

AbbVie (ABBV) and Allergan (AGN) announce Q4 results.

• JNJ Quick QuoteJNJPositive Net Change
• RHHBY Quick QuoteRHHBYPositive Net Change
• MRK Quick QuoteMRKPositive Net Change
• LLY Quick QuoteLLYNegative Net Change
• BMY Quick QuoteBMYPositive Net Change
• AGN Quick QuoteAGNPositive Net Change
• ABBV Quick QuoteABBVPositive Net Change

• pharmaceuticals

Bristol-Myers' (BMY) CAR T Cell Therapy Gets Priority Review

by Zacks Equity Research Published on February 14,2020

Bristol-Myers' (BMY) BLA for lisocabtagene maraleucel gets Priority Review from the FDA.

• GILD Quick QuoteGILDPositive Net Change
• MRK Quick QuoteMRKPositive Net Change
• NVS Quick QuoteNVSPositive Net Change
• BMY Quick QuoteBMYPositive Net Change

• biotechs
• pharmaceuticals

Merck's Keytruda Meets PFS Endpoint in Breast Cancer Study

by Zacks Equity Research Published on February 13,2020

Merck's (MRK) immuno-oncology drug, Keytruda, significantly improves progression free survival as first-line treatment for metastatic triple-negative breast cancer patients in a pivotal study.

• AZN Quick QuoteAZNNegative Net Change
• PFE Quick QuotePFEPositive Net Change
• MRK Quick QuoteMRKPositive Net Change
• BMY Quick QuoteBMYPositive Net Change

• pharmaceuticals

Signs That Your Trading Will Ruin Your Retirement - February 12, 2020

by Zacks Equity Research Published on February 12,2020

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

• RUTH Quick QuoteRUTHPositive Net Change
• DRI Quick QuoteDRINegative Net Change
• MRK Quick QuoteMRKPositive Net Change

• 401k-contributions
• 401k-plan
• retirement
• retirement-cost
• retirement-savings
• retirement-timeline

Top Stock Analyst Reports for Merck, Philip Morris & American Tower

by Mark Vickery Published on February 12,2020

Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Philip Morris International (PM) and American Tower (AMT).

• TMUS Quick QuoteTMUSPositive Net Change
• PM Quick QuotePMPositive Net Change
• MRK Quick QuoteMRKPositive Net Change
• AMT Quick QuoteAMTPositive Net Change
• AMD Quick QuoteAMDNegative Net Change
• AGN Quick QuoteAGNPositive Net Change

• communications
• consumer-discretionary
• medical
• pharmaceuticals
• reit
• semiconductor

Powerful Proof Anyone Can Invest for an Early Retirement - February 11, 2020

by Zacks Equity Research Published on February 11,2020

Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.

• DRI Quick QuoteDRINegative Net Change
• MRK Quick QuoteMRKPositive Net Change
• NJR Quick QuoteNJRPositive Net Change

• 401k-contributions
• 401k-plan
• retirement
• retirement-cost
• retirement-savings
• retirement-timeline
• retiring-early

Incyte's (INCY) Capmatinib NDA Gets Priority Review From FDA

by Zacks Equity Research Published on February 11,2020

The FDA accepts Incyte's (INCY) NDA for capmatinib and grants Priority Review.

• AZN Quick QuoteAZNNegative Net Change
• MRK Quick QuoteMRKPositive Net Change
• INCY Quick QuoteINCYPositive Net Change
• NVS Quick QuoteNVSPositive Net Change

• biotechs

What's in Store for AstraZeneca (AZN) This Earnings Season?

by Zacks Equity Research Published on February 11,2020

AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales.

• AZN Quick QuoteAZNNegative Net Change
• MRK Quick QuoteMRKPositive Net Change
• NKTR Quick QuoteNKTRPositive Net Change
• KPTI Quick QuoteKPTIPositive Net Change

• pharmaceuticals

Seattle Genetics (SGEN) Q4 Earnings Top, Adcetris Drives Sales

by Zacks Equity Research Published on February 07,2020

Seattle Genetics (SGEN) rides high on Q4 earnings and revenue beat.

• RHHBY Quick QuoteRHHBYPositive Net Change
• GSK Quick QuoteGSKPositive Net Change
• MRK Quick QuoteMRKPositive Net Change
• SGEN Quick QuoteSGENPositive Net Change

• biotechs